comparemela.com

Page 2 - Chris Viehbacher News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Biogen to acquire Human Immunology Biosciences in $1 8 billion deal

The biotechnology giant is acquiring Human Immunology Biosciences in an effort to build out its immunology portfolio.

United statesChris viehbacherDrug administrationBiogen head of development priya singhalHuman immunology biosciencesBiogen headDevelopment priya singhalOrphan drug designation

Biogen, looking to diversify, acquires immune drugmaker HI-Bio for $1 15B

BioPharma

Christopher raymondPiper sandlerChris viehbacherReata pharmaceuticalsDive briefHuman immunology biosciencesArch venture partnersMonograph capital

Biogen to Pay Up to $1 8B for Immune Drug Developer

Human Immunology's drug is being developed for a kidney condition called primary membranous nephropathy and for complications after kidney transplants.

Chris viehbacherBiogen incHuman immunology biosciences incHuman immunology biosciencesChief executive officer chris viehbacherBloomberg news

Biogen says hello to HI-Bio, inking $1 15B buyout to expand in immunology

Biogen says hello to HI-Bio, inking $1 15B buyout to expand in immunology
biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.

Chris viehbacherHuman immunology biosciences

Biogen walks away from Ionis-partnered ALS, Angelman prospects

Biogen walks away from Ionis-partnered ALS, Angelman prospects
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomStephanie fradetteChris viehbacherAngelman syndrome foundationBiogen neuromuscular development unitIonis pharmaceuticals partneredNeuromuscular development unitKaryopharm therapeuticsBig biotech

vimarsana © 2020. All Rights Reserved.